Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
An increasing number of patients with polyarticular course juvenile idiopathic arthrtitis are treated biologics great efficacy. Consequently, the importance regarding safety data in general as well especially serious infections, incident autoimmune processes, or malignancies rises. In children, this is crucial concerning occurrences that manifest rarely and only after a prolonged latency period. This study aims to analyze under therapy five most commonly used biologicals for treatment arthritis Germany: abatacept, adalimumab, etanercept, golimumab tocilizumab, control cohort, who received methotrexate. For this, from Biologics Pediatric Rheumatology (BiKeR) Registry were analyzed focus on potential adverse drug reactions like prozesses malignancies. Besides JIA category-specific differences, investigating side effects severe infections development additional processes due crucial. Future clinical randomized double-blinded studies essential direct comparisons, enabling optimal individualized considering comorbidities individual risks. Large patient over (life-)long period beyond childhood particularly important, risk malignancy latency.
Language: Английский